Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6780447 | 1.00 | LMNA (0.44) | LMNAMEN1KMT2ANOS1ADRA2A | |
| SCHEMBL1793108 | 0.79 | LMNA (0.64) | LMNAMEN1KMT2ANOS1GRIN2D | |
| SCHEMBL9060403 | 0.78 | — | — | |
| SCHEMBL1793913 | 0.77 | MEN1 (0.60) | LMNAMEN1KMT2ANOS1GRIN2D | |
| SCHEMBL1792842 | 0.75 | MEN1 (0.64) | LMNAMEN1KMT2ANOS1GRIN2D | |
| SCHEMBL1795317 | 0.75 | MEN1 (0.64) | LMNAMEN1KMT2ANOS1GRIN2D | |
| SCHEMBL1796037 | 0.75 | MEN1 (0.64) | LMNAMEN1KMT2ANOS1GRIN2D | |
| SCHEMBL1626211 | 0.73 | — | — | |
| SCHEMBL9059096 | 0.72 | LMNA (0.50) | LMNAMEN1KMT2ANOS1GRIN2D | |
| SCHEMBL20386670 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871210-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-8822459-B2 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-1790639-B1 | SPIROCYCLIC COMPOUNDS AND THEIR USE AS CXCR4-ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | disclosed |
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8618122-B2 | Compound having acidic group which may be protected, and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-31 | — | — | US | disclosed |
| US-8614323-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| EP-2657235-A1 | Compound containing basic group and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-1942108-B1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8519124-B2 | Chemokine receptor antagonists and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| US-6825191-B2 | ANTICOAGULANT | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030186969-A1 | Benzodiazepine derivatives | AJINOMOTO CO. INC (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1329450-A1 | BENZODIAZEPINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-07-23 | — | — | EP | disclosed |
| EP-0685234-B1 | DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER | NIPPON SHINYAKU CO LTD (JP) | 2000-05-10 | — | — | EP | disclosed |
| US-6020317-A | Glycerol derivative, device and pharmaceutical composition | NIPPON SHINYAKU CO. LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0685457-B1 | GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU CO LTD (JP) | 1999-12-15 | — | — | EP | disclosed |
| US-5705188-A | LIPID MIXTURE, ANTITUMOR AGENTS | NIPPON SHINYAKU COMPANY, LTD. (JP) | 1998-01-06 | — | — | US | disclosed |
| EP-0685457-A1 | GLYCEROL DERIVATIVE, DEVICE AND PHARMACEUTICAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
| EP-0685234-A1 | DRUG COMPOSITION CONTAINING NUCLEIC ACID COPOLYMER | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140072576-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF | CXCR4, CXCR1, CXCR3 | LMNA 4789/4885MEN1 3160/4885KMT2A 3667/4885 |
| US-20030186969-A1 | Benzodiazepine derivatives | GABRA1, F11, GABRA4 | LMNA 2123/4885MEN1 2558/4885KMT2A 1574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.